logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Factor Xa Inhibitor class drugs

    FiltersReset Filters
    3 results

    • eliquis

      (apixaban)
      E.R. Squibb & Sons, L.L.C.
      Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.

    • savaysa

      (EDOXABAN TOSYLATE)
      Daiichi Sankyo Inc.
      Usage: SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism after initial therapy with a parenteral anticoagulant. It should not be used in patients with CrCL > 95 mL/min.

    • xarelto

      (rivaroxaban)
      Janssen Pharmaceuticals, Inc.
      Usage: XARELTO is indicated for reducing the risk of stroke in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing DVT after hip or knee replacement, and reducing major cardiovascular events in coronary artery disease. It's also used in pediatric patients for VTE treatment and prevention.